Brokerages Anticipate Kala Pharmaceuticals Inc (KALA) Will Announce Earnings of -$0.52 Per Share

Share on StockTwits

Brokerages expect that Kala Pharmaceuticals Inc (NASDAQ:KALA) will report earnings per share (EPS) of ($0.52) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Kala Pharmaceuticals’ earnings, with estimates ranging from ($0.60) to ($0.45). Kala Pharmaceuticals posted earnings per share of ($0.46) during the same quarter last year, which would indicate a negative year over year growth rate of 13%. The company is expected to report its next quarterly earnings results on Monday, March 25th.

On average, analysts expect that Kala Pharmaceuticals will report full year earnings of ($2.20) per share for the current fiscal year, with EPS estimates ranging from ($2.30) to ($2.11). For the next fiscal year, analysts forecast that the firm will report earnings of ($2.39) per share, with EPS estimates ranging from ($2.84) to ($2.03). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.63) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.01).

A number of research firms have recently weighed in on KALA. Zacks Investment Research cut shares of Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 22nd. ValuEngine cut shares of Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, December 21st. HC Wainwright set a $15.00 price target on shares of Kala Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, November 9th. Wedbush set a $51.00 price target on shares of Kala Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, January 16th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Kala Pharmaceuticals from $35.00 to $22.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $21.70.

Shares of NASDAQ:KALA traded up $0.14 on Monday, reaching $6.65. 124,700 shares of the company were exchanged, compared to its average volume of 203,480. The company has a quick ratio of 6.27, a current ratio of 6.34 and a debt-to-equity ratio of 0.30. Kala Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $18.30. The stock has a market cap of $217.17 million, a PE ratio of -1.14 and a beta of 1.30.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Trexquant Investment LP acquired a new stake in Kala Pharmaceuticals in the 3rd quarter valued at about $140,000. Rhumbline Advisers acquired a new stake in Kala Pharmaceuticals in the 4th quarter valued at about $75,000. Virtu Financial LLC acquired a new stake in Kala Pharmaceuticals in the 3rd quarter valued at about $200,000. Bradley Foster & Sargent Inc. CT acquired a new stake in Kala Pharmaceuticals in the 4th quarter valued at about $115,000. Finally, Engineers Gate Manager LP acquired a new stake in Kala Pharmaceuticals in the 3rd quarter valued at about $249,000. 48.38% of the stock is currently owned by hedge funds and other institutional investors.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

See Also: How dollar cost averaging works

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokerages Anticipate Kala Pharmaceuticals Inc  Will Announce Earnings of -$0.52 Per Share
Brokerages Anticipate Kala Pharmaceuticals Inc Will Announce Earnings of -$0.52 Per Share
IDOL COIN Trading Down 37% Over Last Week
IDOL COIN Trading Down 37% Over Last Week
Zacks: Brokerages Expect Tilray Inc  Will Post Quarterly Sales of $17.32 Million
Zacks: Brokerages Expect Tilray Inc Will Post Quarterly Sales of $17.32 Million
Rexford Industrial Realty Inc  Expected to Announce Earnings of $0.27 Per Share
Rexford Industrial Realty Inc Expected to Announce Earnings of $0.27 Per Share
Mercer International Inc.  Short Interest Up 1,555.6% in January
Mercer International Inc. Short Interest Up 1,555.6% in January
Short Interest in TrueCar Inc  Increases By 14.3%
Short Interest in TrueCar Inc Increases By 14.3%


Leave a Reply

© 2006-2019 Ticker Report